Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $16.56 Consensus Target Price from Brokerages

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have received an average recommendation of “Buy” from the eleven analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $16.5556.

A number of research analysts have issued reports on IVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Cantor Fitzgerald assumed coverage on Inventiva in a research report on Friday, July 17th. They set an “overweight” rating for the company.

Inventiva Stock Performance

IVA stock opened at $4.54 on Friday. The company has a fifty day moving average of $4.29 and a 200-day moving average of $5.32. Inventiva has a one year low of $2.85 and a one year high of $7.98.

Hedge Funds Weigh In On Inventiva

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVA. Creative Planning bought a new stake in Inventiva in the second quarter worth $32,000. Commonwealth Equity Services LLC raised its holdings in Inventiva by 19.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after buying an additional 12,704 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Inventiva in the fourth quarter worth about $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva in the fourth quarter worth about $84,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Inventiva during the 3rd quarter worth about $116,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.